Luson Bioventures' Founder Derek Small learned his tech investment banking background was useless in biotech. The investors, 15-year timelines to revenue, and financial models were entirely different, forcing him to learn a new fundraising playbook from scratch.
Lacking capital, Derek Small was forced to personally write grants and lead regulatory affairs. This hands-on, "virtual company" approach, born of necessity, gave him a profound, holistic understanding of the science and operations he wouldn't have gained otherwise.
Founder Derek Small's career was imprinted by two key moments: an oncology patient stabilizing for five years on a first dose, and depression patients calling to say his drug "literally changed my life." These direct impacts provided a powerful, mission-driven focus.
While running a public company in a different field, Derek Small's experience as primary caregiver for his father with dementia was so profound it triggered his CEO succession plan and caused him to pivot his firm, Luson Bioventures, to a 100% focus on CNS.
Derek Small argues the breakthrough in neuroscience mirrors oncology's shift from blunt instruments to targeted therapies. By focusing on underlying pathology like synaptic dysfunction and neuroinflammation, rather than just symptoms, developers can achieve biomarker-based approvals and more effective treatments.
Derek Small posits that GLP-1s succeed in metabolic disease by modulating a "network phenomenon," not a single target. He applies this thesis to neuroscience, focusing on synaptic function and neuroinflammation as the core network that can create systemic brain resilience, similar to how GLP-1s impact metabolic health.